Acumen Pharmaceuticals (ABOS) vs Dyadic International (DYAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dyadic International (DYAI) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 68.8% versus a loss of 88.1%. Over five years, DYAI leads with a -92.2% price change compared with -97.7% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $11.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | DYAI |
|---|---|---|
| Share price | $0.1865 | $0.287 |
| Market cap | $13.49M | $11.51M |
| 1-day change | -3.52% | -7.66% |
| YTD return | -91.16% | -69.47% |
| 1-year return | -88.12% | -68.80% |
| 5-year return | -97.74% | -92.24% |
| EPS (TTM) | $-1.55 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.09M |
| Revenue growth (YoY) | — | -11.59% |
| Net income (latest FY) | $-121.33M | $-7.36M |
| Gross margin | — | 24.93% |
| Operating margin | — | -232.75% |
| Net margin | — | -238.31% |
| 52-week high | $3.60 | $1.60 |
| 52-week low | $0.16 | $0.285 |
| Distance from 52-week high | -94.82% | -82.06% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +3975.07% | +1816.38% |
| Average volume | 2.73M | 140.81K |
| Shares outstanding | 72.33M | 40.09M |
| Employees | 60 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed ABOS by 19.3 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
ABOS vs DYAI FAQ
Which is bigger, Acumen Pharmaceuticals or Dyadic International?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $11.51M for Dyadic International (DYAI).
Which stock has performed better over the past year, ABOS or DYAI?
DYAI returned -68.80% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Dyadic International in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.